SCHEMBL17685258

SCHEMBL17685258

Cc1ccc(Nc2ncc(C)c(Nc3cccc(CNS(=O)(=O)N(C)C)c3)n2)cc1S(N)(=O)=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 6/20 0.51
BTK Q06187 4/20 0.51
BRD4 O60885 1/20 0.50
JAK3 P52333 13/20 0.49
JAK1 P23458 10/20 0.49
SYK P43405 5/20 0.49
ITK Q08881 3/20 0.49
PLK4 O00444 2/20 0.49
AURKA O14965 2/20 0.49
PDPK1 O15530 2/20 0.49
DAPK3 O43293 2/20 0.49
JAK2 O60674 2/20 0.49
MAP4K4 O95819 2/20 0.49
PAK4 O96013 2/20 0.49
CHEK2 O96017 2/20 0.49
ERBB2 P04626 2/20 0.49
NTRK1 P04629 2/20 0.49
PRKCG P05129 2/20 0.49
INSR P06213 2/20 0.49
LCK P06239 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17685281 0.91 JAK3 (0.56) EGFRBTKBRD4JAK3JAK1
SCHEMBL17685307 0.90 JAK3 (0.59) EGFRBTKBRD4JAK3JAK1
SCHEMBL2474134 0.88 EGFR (0.52) EGFRBTKJAK3JAK1SYK
SCHEMBL4973231 0.86 BRD4 (0.53) EGFRBTKBRD4JAK3JAK1
SCHEMBL2471890 0.85 JAK3 (0.63) EGFRBTKBRD4JAK3JAK1
SCHEMBL4973352 0.81 SYK (0.58) EGFRBTKJAK3JAK1SYK
SCHEMBL2470647 0.81 CDK2 (0.53) EGFRBTKBRD4JAK3JAK1
SCHEMBL4970836 0.81 EGFR (0.51) EGFRBTKBRD4JAK3JAK1
SCHEMBL4973302 0.80 JAK3 (0.52) EGFRBTKBRD4JAK3JAK1
SCHEMBL2474786 0.79 JAK3 (0.56) EGFRBTKJAK3JAK1SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2370415-B1 COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY RIGEL PHARMACEUTICALS INC (US) 2016-04-20 EP claimed
EP-2370415-B1 COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY RIGEL PHARMACEUTICALS INC (US) 2016-04-20 EP disclosed